Navigation Links
REGiMMUNE to present GvHD data at the 50th ASH Annual Meeting
Date:12/5/2008

Mountain View, CA December 5, 2008 REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, will present preclinical data on the company's potential therapeutic treatment for Graft versus Host Disease (GvHD) at the American Society of Hematology Annual Meeting being held December 6 through 9 in San Francisco, California. REGiMMUNE is developing KRN7000 (RGI-2001) as a new immunosuppressant for GvHD associated with stem cell transplantation. Two posters will be presented at ASH on the evenings of Sunday December 7 and Monday December 8, respectively.

Abstract/Poster II-426
Sunday, December 7: 6:00 PM - 8:00 PM
Donor-Specific Tolerance Induction through Expansion of DCregs and Tregs by a Liposomal Formulation of KRN7000 (RGI-2001)

Abstract/Poster III-582
Monday, December 8: 5:30 PM - 7:30 PM
A Liposomal Formulation of KRN7000 (RGI-2001) Potently Reduces GvHD Lethality through the Expansion of CD4+Foxp3+ Regulatory T cells in Murine Models.

"We are delighted to present our progress on RGI-2001 development at the 50th ASH Annual Meeting," said Mr. Haru Morita, President and Chief Executive Officer, REGiMMUNE. "This is a great opportunity to provide an update on our pre-IND stage product candidate, RGI-2001, which is in a preclinical study for GvHD associated with bone marrow transplantation. The company is also developing RGI-2001 for solid organ transplantation. Our mission is to develop novel therapies for immune disorders including allergies, autoimmune diseases and transplantation. We believe the success of RGI-2001 will be the first demonstration of the promise of our proprietary technology and of the company's significant development capabilities."


'/>"/>

Contact: Debra Bannister
530-676-8001
REGiMMUNE
Source:Eurekalert

Page: 1

Related medicine news :

1. 11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions
2. Aflac Incorporated To Present at the Goldman Sachs U.S. Financial Services Conference 2008
3. Inverness Medical Innovations to Present at RBC Capital Markets 2008 Healthcare Conference on December 11, 2008
4. MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
5. Zevalin Data to be Presented at ASH 2008
6. MAP Pharmaceuticals to Present at the 2008 RBC Capital Markets Healthcare Conference
7. Medicsight PLC Presents New Data at RSNA 2008 Further Supporting Relevance of Computer-Aided Detection (CAD) and Image Analysis Software in Early Colon Cancer Screening and Diagnosis
8. Cardium Announces Investor Presentation and Corporate Update Webcast
9. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting
10. LCA-Vision to Present at RBC Capital Markets 2008 Healthcare Conference
11. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...ociation and Zinedine Zidane, its emblematic ambas...e results regaring the gene therapy in adrenoleuko...shed in the prestigious journal Science. Two child... halted. The children are doing well, which is une...w months. This discovery opens up treatment perspe...
(Date:11/5/2009)...K, Nov. 5 Wolters Kluwer Health ha...MSN, RN, CRNP, ANP-BC, to the new position of Chie...e nursing strategy of its Lippincott Williams &... leading international publisher of medical and nu...ronic medical, scientific, and academic informatio...
(Date:11/5/2009)...CSBURG, Pa., Nov. 5 Sele... SEM ), the parent of Select Medical Corporation, ...d September 30, 2009. ,, For the third quarter ...ncreased 5.1% to $545.6 million compared to $519.2... from operations decreased 9.0% to $32.9 million c...
(Date:11/5/2009)...BROKE, Bermuda, Nov. 5 A... AWH ) today reported net income of $200.6 millio...er of 2009 compared to a net,loss of $46.4 million...r of,2008. Net income for the nine months ended S... diluted share, compared to net income of,$163.8 m...
(Date:11/5/2009)...ELES, Nov. 5 Narconon Internationa...ts drug rehabilitation and education centers throu...th thousands of students and other community membe...ly Partnership,s (NFP) Red Ribbon Week is consider...tivities and is held during the end of October eac...
Breaking Medicine News(10 mins):Health News:2 children suffering from adrenoleukodystrophy saved thanks to the ELA Association 2Health News:2 children suffering from adrenoleukodystrophy saved thanks to the ELA Association 3Health News:2 children suffering from adrenoleukodystrophy saved thanks to the ELA Association 4Health News:Wolters Kluwer Health Appoints Anne Woods to Chief Nursing Officer; Strengthens Its Commitment to the Nursing Market 2Health News:Wolters Kluwer Health Appoints Anne Woods to Chief Nursing Officer; Strengthens Its Commitment to the Nursing Market 3Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 2Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 3Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 4Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 5Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 6Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 7Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 8Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 9Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 10Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 11Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 12Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 13Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 14Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 15Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 16Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 17Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 18Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 19Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 20Health News:Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 21Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 2Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 3Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 4Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 5Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 6Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 7Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 8Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 9Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 10Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 11
...ion (FDA) and Roxane Labs have issued a nationwide...ed in patients with severe// rheumatoid arthritis ...t rejection. "It was discovered that a single...bottle, which was not dispensed to a patient, the ...
...sung has developed a device that can measures body... electrodes that the user touches with the thumb a...ent through the body, measuring the voltage drop a...ult diseases. Since fat occupies 17 percent...
...e treatment of recurrent ovarian cancer ignoring t...mzar in combination with carboplatin (chemotherapy...n cancer. The drug Gemzar also known by its gener...ncer Society about 22,000 women are diagnosed with...
... are two of the main causes of growing infertility...s unable to conceive// normally. "Worldwide...iving. About 50 percent of the infertility problem...noted infertility specialist Rajeev Agarwal. ...
... a memorandum of understanding (MOU) with the Clin... the supply of affordable//, high- quality drugs a...are. The MoU was signed at the Presidential Vi...agreement, Nigeria is to be included in the Clinto...
... of Health (MOH) says that Singapore will soon con... Pandemic Readiness.// More than 1,000 pers...e MOH, the Ministry of Education, the Civil Aviati...I. The two-day emergency exercise endeavors...
Other Medicine News:Health News:Stress and Pollution are Major Cause of Infertility Among Urban Couples 2
(Date:11/5/2009)...Nov. 5 Virtual Health Te...ced today that it has entered into a Letter of Int...d Management Technologies, Inc. (WNDM). The deal p... debt, 4,000,000 shares of WNDM stock and a royalt...closed at $2.00 per share on 11/4/09 and VHGI clos...
(Date:11/5/2009)...SCO, Calif., Nov. 5 Sune...nnounced that the U.S. Food and Drug Administratio...r the treatment of acute myeloid leukemia (AML). S...l trials of voreloxin in AML: a single-agent study...ed elderly AML patients unlikely to benefit from s...
(Date:11/5/2009).... 5 Transgenomic, Inc. (...Webcast: , , What: Transgenomic, Inc. Thir...erence Call, When: Thursday, November 5, 2...tp://www.transgenomic.com/events.asp?id=6, targe...ts.asp?id=6,>http://www.transgenomic.com/events....
Breaking Medicine Technology:OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010 2OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010 3Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 2Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 3Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast 2The Lustgarten Foundation Says Patrick Swayzes Death Highlights the Need for Increased Research into Early Diagnosis and Treatment of Pancreatic Cance 57253 1The Lustgarten Foundation Says Patrick Swayzes Death Highlights the Need for Increased Research into Early Diagnosis and Treatment of Pancreatic Cance 57253 2Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects New Report Says 5006 1Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects New Report Says 5006 2Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects New Report Says 5006 3Anxious Kids at Risk for Obesity in Adulthood 57251 1Anxious Kids at Risk for Obesity in Adulthood 57251 2
...mary Endpoints Achieved for SCOLR,s 12-Hour ..., Nov. 7 SCOLR Pharma, Inc.,(Amex: DDD ) today r...onths,ended September 30, 2008. The Company will h..., at 11:30 a.m. (Eastern Standard Time)., Daniel ..."We had a very,productive third quarter making sig...
...Pharmaceuticals,Inc. (Nasdaq: CADX ), a biopharma...g and commercializing proprietary product candidat...day reported financial results for the,third quart... company also provided an update on the clinical d...candidates -- Acetavance(TM), an,intravenous formu...
Other Medicine Technology:SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results 8Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 2Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 3Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 4Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 5Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 6Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 7Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 8
...ontinuous random access capabilities to immunodiag...d, anemia, cardiac, reproductive, endocrinology, o...available, with infectious disease assays under de...ss 60 accessible samples for a throughput of 90 pa...
Myoglobin IRMA Kit
...r the quantitative determination of prolactin in h...and treatment of disorders of the anterior pituita...tative Test is based on the principle of a solid p...system utilized sheep anti-prolactin for solid pha...
Prolactin Radioimmunoassay
Medicine Products: